Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

May

Today In Oncology

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Related Videos

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

FDA Approves Durvalumab Plus BCG for High-Risk NMIBC

Local Radiotherapy May Help Control Oligometastatic Breast Cancer

TAILORx and RxPONDER Trials Shift to a Discovery Platform

Radiotherapy for Prostate Cancer: HERMES Trial Compares Two and Five Fractions

BPDCN FDA Approves Pivekimab Sunirine-pvzy